{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:06:28Z","timestamp":1787169988871,"version":"build-2736575974"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n                    <jats:title>Context:<\/jats:title>\n                    <jats:p>The pathological progression in severe Coronavirus Disease 2019 (COVID-19) includes an excessive and unregulated pro-inflammatory cytokine storm. Though the efficacy of corticosteroids like methylprednisolone (MPS) in severe COVID-19 is proven now, its dose and duration are not precise.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>Our study aimed to compare the effect of a standard dose (SD) of MPS (60\u2013120 mg\/day) to a high dose (HD) of MPS (&gt;120 mg\/day) on the outcome of hospitalized COVID-19 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Settings and Design:<\/jats:title>\n                    <jats:p>This study was a cross-sectional study. Patients admitted to AIIMS, Bhopal\u2019s intensive care unit (ICU) from July 2020 to March 2021 were enrolled in the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and Material:<\/jats:title>\n                    <jats:p>The patient\u2019s medical records were extracted from the medical record section of the hospital. The primary endpoint was the all-cause mortality during the hospital stay. The secondary endpoints were the need for mechanical ventilation, the use of vasopressors, the occurrence of acute kidney injury (AKI), and secondary infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Statistical Analysis Used:<\/jats:title>\n                    <jats:p>Data were entered in the MS Excel spreadsheet and coded appropriately.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Our data showed that survival, the need for mechanical ventilation, the occurrence of AKI, and secondary bacterial infection are comparable among the two groups with no significant difference. The logistic regression analysis showed that there is a slightly higher risk of death for patients with an acute respiratory distress syndrome (ARDS) receiving HD of corticosteroids compared to SD, though these results were found to be statistically non-significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In hospitalized patients suffering from severe COVID-19 pneumonia, an SD of MPS is as effective as an HD of MPS in terms of reduction in mortality and need for mechanical ventilation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jfmpc.jfmpc_908_21","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T06:06:24Z","timestamp":1638425184000},"page":"4066-4071","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of standard dose with high dose of methylprednisolone in the management of COVID-19 patients admitted in ICU"],"prefix":"10.4103","volume":"10","author":[{"given":"Abhishek","family":"Singhai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parneet Kaur","family":"Bhagtana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Pawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Sai","family":"Pavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20-20240828","doi-asserted-by":"crossref","first-page":"108393","DOI":"10.1016\/j.clim.2020.108393","article-title":"The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19):The experience of clinical immunologists from China","volume":"25","author":"Zhang","year":"2020","journal-title":"Clin Immunol"},{"key":"R2-20-20240828","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.healun.2020.03.012","article-title":"COVID-19 illness in native and immunosuppressed states:A clinical-therapeutic staging proposal","volume":"39","author":"Siddiqi","year":"2020","journal-title":"J Heart Lung Transplant"},{"key":"R3-20-20240828","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"R4-20-20240828","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir Med"},{"key":"R5-20-20240828","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Horby","year":"2021","journal-title":"N Engl J Med"},{"key":"R6-20-20240828","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s00134-017-4914-x","article-title":"Critical illness-related corticosteroid insufficiency (CIRCI):A narrative review from a multispecialty task force of the Society of critical care medicine (SCCM) and the European society of intensive care medicine (ESICM)","volume":"43","author":"Annane","year":"2017","journal-title":"Intensive Care Med"},{"key":"R7-20-20240828","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1378\/chest.124.1.12","article-title":"Severe acute respiratory syndrome","volume":"124","author":"Hui","year":"2003","journal-title":"Chest"},{"key":"R8-20-20240828","doi-asserted-by":"crossref","first-page":"e13458","DOI":"10.1111\/eci.13458","article-title":"High-dose methylprednisolone in nonintubated patients with severe COVID-19 pneumonia","volume":"51","author":"Papamanoli","year":"2021","journal-title":"Eur J Clin Investig"},{"key":"R9-20-20240828","doi-asserted-by":"crossref","first-page":"e00596","DOI":"10.1002\/rcr2.596","article-title":"High-dose, short-term corticosteroids for ARDS caused by COVID- 19:A case series","volume":"8","author":"So","year":"2020","journal-title":"Respirol Case Rep"},{"key":"R10-20-20240828","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/cid\/ciaa601","article-title":"COVID-19 management task force. Early short-course corticosteroids in hospitalized patients with COVID-19","volume":"71","author":"Fadel","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R11-20-20240828","doi-asserted-by":"crossref","first-page":"104380","DOI":"10.1016\/j.jcv.2020.104380","article-title":"Supportive treatment with tocilizumab for COVID-19:A systematic review","volume":"127","author":"Alzghari","year":"2020","journal-title":"J Clin Virol"},{"key":"R12-20-20240828","doi-asserted-by":"crossref","first-page":"110267","DOI":"10.1016\/j.biopha.2020.110267","article-title":"Emerging pharmacotherapies for COVID-19","volume":"128","author":"Salvi","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"R14-20-20240828","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4103\/0970-2113.80324","article-title":"Corticosteroids and ARDS:A review of treatment and prevention evidence","volume":"28","author":"Khilnani","year":"2011","journal-title":"Lung India"},{"key":"R16-20-20240828","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41392-020-0158-2","article-title":"A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia","volume":"5","author":"Wang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"R17-20-20240828","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/s12879-021-06045-3","article-title":"Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients:A triple-blinded randomized controlled trial","volume":"21","author":"Ranjbar","year":"2021","journal-title":"BMC Infect Dis"},{"key":"R18-20-20240828","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.chest.2020.10.054","article-title":"Impact of corticosteroids in coronavirus disease 2019 outcomes","volume":"159","author":"Cano","year":"2021","journal-title":"Chest"},{"key":"R19-20-20240828","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jiph.2021.06.003","article-title":"Intravenous methylprednisolone with or without tocilizumab in patients with severe COVID-19 pneumonia requiring oxygen support:A prospective comparison","volume":"14","author":"Hamed","year":"2021","journal-title":"J Infect Public Health"},{"key":"R20-20-20240828","doi-asserted-by":"crossref","first-page":"670170","DOI":"10.3389\/fphar.2021.670170","article-title":"Systemic corticosteroid administration in Coronavirus disease 2019 outcomes:An umbrella meta-analysis incorporating both mild and pulmonary fibrosis-manifested severe disease","volume":"12","author":"Cheng","year":"2021","journal-title":"Front Pharmacol"}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_908_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:16:13Z","timestamp":1787166973000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_908_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_908_21","relation":{},"ISSN":["2249-4863"],"issn-type":[{"value":"2249-4863","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]}}}